University of Missouri researchers are working to develop the first-ever vaccine proven to protect cattle from a devastating tick-borne cattle disease known as bovine anaplasmosis.
J&J seeks label expansion for Tremfya in ulcerative colitis – Pharmaceutical Technology
Share this article J&J’s Tremfya is forecast to generate $6.5bn in sales in 2030, according to GlobalData. Credit: Michael Vi via Shutterstock. Johnson & Johnson